XNAS · Healthcare · Biotechnology
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | Q1 2026 | -0.81 | -0.90 | -11.11% | $495,000 | ❌ Miss | +5.67% | -13.70% | — |
| 2026-03-25 | Q4 2025 | -1.00 | -0.80 | +20.00% | $420,000 | ✅ Beat | +8.77% | +56.14% | +81.14% |
| 2025-11-13 |
| Q3 2025 |
| -0.15 |
| -0.13 |
| +13.33% |
| $183,000 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-13 | Q2 2025 | — | -0.18 | — | $338,000 | ✅ Beat | +4.48% | +9.94% | +19.65% |
| 2025-03-27 | Q4 2024 | -0.89 | -0.90 | -1.12% | $67,000 | ❌ Miss | -22.73% | -36.82% | -42.27% |
| 2024-11-13 | Q3 2024 | -1.13 | -1.10 | +2.65% | $68,000 | ✅ Beat | -22.22% | -14.68% | -21.03% |
| 2024-08-13 | Q2 2024 | -1.50 | -1.03 | +31.33% | $0 | ✅ Beat | -17.46% | -0.33% | -14.83% |
| 2024-05-14 | Q1 2024 | -3.75 | -4.75 | -26.67% | $0 | ❌ Miss | -11.87% | +4.70% | -63.56% |
Showing last 8 quarters.